ClinicalTrials.gg
Not yet recruitingNCT07703423Updated Jul 14, 2026

Optimizing Care For Management Of Hard To Control Hypertension In Low-Income Patients Across Family Health Centers In New York City

An interventional study of Multilevel Hypertension Care Model in Hypertension, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
628
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by NYU Langone Health — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · NYU Langone Health.

Planned enrollment
10th of 39
628 · median 300
Started
2027
the only one that year
No phase
31 of 44
6 open now
Registered
44th of 44
by date

Among the 44 studies in Hypertension by NYU Langone Health, this one is the 10th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2027, is one of 31 with no phase, and was the 44th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 44 studies in Hypertension by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by NYU Langone Health, or all of them as a file.
02

Study summary

This study will develop and evaluate a multilevel implementation strategy to improve management of hard-to-control hypertension among low-income adults receiving care at the Family Health Centers at NYU Langone Health, a network of federally qualified health centers (FQHCs) in New York City.

Using a hybrid mixed-methods implementation science design, the study will be conducted across 9 primary care locations over three phases: a pre-implementation phase to identify contextual barriers using the Consolidated Framework for Implementation Research (CFIR); an implementation phase to deploy and evaluate a multilevel care model; and a post-implementation phase to develop a pragmatic toolkit for scale-up.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient aged 18 years or older receiving primary care at one of the nine participating Family Health Centers at NYU Langone Health locations in Brooklyn, New York City.
  • Active primary care patient at a participating Family Health Centers location, defined as having at least one documented primary care encounter in the Epic electronic health record within the 24 months prior to the index encounter.
  • Documented hard-to-control hypertension, defined as blood pressure ≥140/90 mmHg based on clinic blood pressure values and, where available, validated home blood pressure readings documented in the electronic health record, in a patient already receiving two or more antihypertensive agents.
  • Current prescription of two or more antihypertensive medications documented in the Epic medication list at the index encounter.
  • Willingness and ability to participate in study procedures, including home blood pressure telemonitoring, telehealth-based medication review by the nurse case manager via telephone or video visit, and automated SMS pre-visit activation messages. Patients with digital literacy challenges, difficulty transmitting home readings, or other operational barriers will receive CHW support to facilitate participation, consistent with the CHW navigation model embedded in the multilevel care model.
  • Provision of or, where applicable under the IRB-approved protocol, a waiver of informed consent for EHR-based data extraction and registry-based outcome ascertainment.

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years at the time of the index encounter.
  • No active primary care relationship at a participating Family Health Centers location, defined as fewer than one completed primary care encounter in the Epic EHR in the 12 months prior to the index encounter.
  • Blood pressure at the index encounter does not meet the study definition of hard-to-control hypertension (BP ≥140/90 mmHg on two or more antihypertensive medications).
  • Confirmed secondary cause of hypertension (examples include kidney disease, renovascular disease, primary aldosteronism, obstructive sleep apnea, thyroid disorders, and medication- or substance-induced hypertension, such as that caused by NSAIDs, , oral , or stimulants) where treatment of the underlying condition is the primary indicated management.
  • Current enrollment in hospice or palliative care.
  • End-stage renal disease requiring dialysis at the time of the index encounter.
  • Documented cognitive impairment or dementia that would preclude participation in home blood pressure telemonitoring or telehealth visits, as determined by clinical documentation in the EHR.
  • Known pregnancy at the time of the index encounter. Pregnant persons are not included in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
628 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants who attend FHCs assigned to receive the multilevel care model intervention.

    Behavioral: Multilevel Hypertension Care Model

  • No intervention
    Control

    Participants who attend FHCs that were not assigned to receive the multilevel care model intervention.

Interventions

  • BehavioralMultilevel Hypertension Care Model

    The intervention is delivered through the existing My Virtual Care (MVC) Epic-integrated team-based virtual high-risk clinic infrastructure and is adapted specifically for patients with hard-to-control hypertension. It is organized across four levels: 1. Patient-Level Strategies (Individual delivery, remote and in-person) 2. Provider and Health System-Level Strategies (EHR-embedded) 3. Community-Level Strategies (Individual, CHW-navigated) 4. Implementation Support

06

What researchers measure

Primary outcomes

  1. Change in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Time to Treatment Intensification

    Defined as the number of days from the index encounter meeting criteria for hard-to-control hypertension to the first prescription of a new antihypertensive class or dose increase of an existing blood pressure medication that was not present at the index encounter.

    Time frame: Up to Month 12

  2. Blood Pressure Control - Guideline Metric

    Defined as the proportion of patients achieving controlled blood pressure at the guideline-relevant threshold of \<130/80 mmHg.

    Time frame: Month 6, Month 12

  3. Blood Pressure Control - Performance Metric

    Defined as the proportion of patients achieving controlled blood pressure at the performance metric threshold of \<140/90 mmHg

    Time frame: Month 6, Month 12

  4. Use of Mineralocorticoid Antagonists

    Proportion of patients who report use of mineralocorticoid antagonists.

    Time frame: Up to Month 12

  5. Use of Single-Pill Combinations

    Proportion of patients who report use of single-pill combinations.

    Time frame: Up to Month 12

  6. Use of Long-acting Thiazide Diuretics

    Proportion of patients who report use of long-acting thiazide diuretics.

    Time frame: Up to Month 12

  7. Time to Completed Follow-up Visit

    Time to completed follow-up visit (remote or in person) after an encounter with hard-to-control hypertension as a marker of care process efficiency.

    Time frame: Up to Month 12

  8. Change in Life's Essential 8 Components Score

    Assessment of cardiovascular health using eight key components-four lifestyle behaviors and four health factors. Each component is scored from 0 to 100; the total score is the average of the components and ranges from 0-100; higher scores indicate greater cardiovascular health.

    Time frame: Baseline, Month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Coded study data may be shared with other researchers for future research related to hypertension management, implementation science, health equity, cardiovascular outcomes, and health-related social needs in safety-net settings, for participants who consent to optional future data storage and use. Shared data will not include direct identifiers. The link between the code and participant identity will remain with the Principal Investigator at NYU Langone Health and will not be shared with outside researchers. Such data may become available after completion of the study and publication of the primary study findings. Data may be retained indefinitely by NYU Langone Health, subject to participant consent for optional future data storage and use, institutional policies, sponsor requirements, IRB requirements, and applicable confidentiality protections. Participants may withdraw permission for future use, after which stored data will not be used for new analyses.

Supporting information: Study protocol

Time frame: Coded study data may become available after completion of the study and publication of the primary study findings. Data may be retained indefinitely by NYU Langone Health, subject to participant consent for optional future data storage and use, NYU Langone institutional policies, AstraZeneca sponsor requirements, IRB requirements, and applicable confidentiality protections. Participants may withdraw permission for future use, after which stored data will not be used for new analyses.

Access criteria: Access will be limited to qualified researchers whose proposed use of the coded data is reviewed and approved by the Principal Investigator and/or NYU Langone Health, consistent with institutional policies, IRB requirements, AstraZeneca sponsor requirements, and applicable confidentiality protections. The code key linking data to participant identity will remain with the Principal Investigator at NYU Langone Health and will not be shared with outside researchers. Requests should be directed to Olugbenga.ogedegbe@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Jan 2028, 11 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 14, 2026
StartEst.
Feb 2027
Primary completionEst.
Jan 2028
CompletionEst.
Jun 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07703423
Lead sponsor
NYU Langone Health
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Feb 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Olugbenga Ogedegbe, MD
Contact
Olugbenga.ogedegbe@nyulangone.org
646-501-3435
Valy Fontil
Contact
Valy.Fontil@nyulangone.org
646-501-3753
Olugbenga Ogedegbe, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion